455 related articles for article (PubMed ID: 28239463)
1. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
[TBL] [Abstract][Full Text] [Related]
2. PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer.
Nada MH; Wang H; Hussein AJ; Tanaka Y; Morita CT
Oncoimmunology; 2021; 10(1):1989789. PubMed ID: 34712512
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Immunomodulatory Activity of Fluorine-Containing Bisphosphonates.
Mizuta S; Tagod MSO; Iwasaki M; Nakamura Y; Senju H; Mukae H; Morita CT; Tanaka Y
ChemMedChem; 2019 Feb; 14(4):462-468. PubMed ID: 30637982
[TBL] [Abstract][Full Text] [Related]
4. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug.
Tanaka Y; Murata-Hirai K; Iwasaki M; Matsumoto K; Hayashi K; Kumagai A; Nada MH; Wang H; Kobayashi H; Kamitakahara H; Okamura H; Sugie T; Minato N; Toi M; Morita CT
Cancer Sci; 2018 Mar; 109(3):587-599. PubMed ID: 29288540
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.
Sakamoto M; Nakajima J; Murakawa T; Fukami T; Yoshida Y; Murayama T; Takamoto S; Matsushita H; Kakimi K
J Immunother; 2011 Mar; 34(2):202-11. PubMed ID: 21304399
[TBL] [Abstract][Full Text] [Related]
8. Expansion of human peripheral blood γδ T cells using zoledronate.
Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
[TBL] [Abstract][Full Text] [Related]
9. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses.
Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M
J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells.
Okuno D; Sugiura Y; Sakamoto N; Tagod MSO; Iwasaki M; Noda S; Tamura A; Senju H; Umeyama Y; Yamaguchi H; Suematsu M; Morita CT; Tanaka Y; Mukae H
Front Immunol; 2020; 11():1405. PubMed ID: 32793196
[TBL] [Abstract][Full Text] [Related]
11. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
12. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Poonia B; Pauza CD
Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
[TBL] [Abstract][Full Text] [Related]
13. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
14. Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism.
Wang H; Sarikonda G; Puan KJ; Tanaka Y; Feng J; Giner JL; Cao R; Mönkkönen J; Oldfield E; Morita CT
J Immunol; 2011 Nov; 187(10):5099-113. PubMed ID: 22013129
[TBL] [Abstract][Full Text] [Related]
15. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
[TBL] [Abstract][Full Text] [Related]
16. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.
Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H
J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349
[TBL] [Abstract][Full Text] [Related]
17. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy.
Yoshikawa T; Takahara M; Tomiyama M; Nieda M; Maekawa R; Nakatsura T
Int J Oncol; 2014 Nov; 45(5):1847-56. PubMed ID: 25189159
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis
Shen H; Yang E; Guo M; Yang R; Huang G; Peng Y; Sha W; Wang F; Shen L
Emerg Microbes Infect; 2022 Dec; 11(1):1790-1805. PubMed ID: 35765887
[TBL] [Abstract][Full Text] [Related]
19. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
